- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02643459
Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage (suPAR)
Introduction of Soluble Urokinase Plasminogen Activating Receptor in Acute Care as a Prognostic Biomarker to Strengthen Risk Stratification of Acutely Admitted Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In a health care system where the general population is growing, more patients are living with chronic conditions and the hospitals are reducing beds and length of stay, it is crucial to perform safe and fast risk stratification of patients presenting in the Emergency departments. Risk stratification is currently performed with a combination of measurement of the vital signs and assessment of the primary complaint. The aim of the current study is to assess whether the supplement of biomarkers can improve the risk stratification in regard to mortality, readmissions and improve overall patient flow in the Emergency departments. Soluble urokinase plasminogen activating receptor (suPAR) is the soluble form of urokinase-type plasminogen activator receptor (uPAR). uPAR is present on various immunological active cells, as well as endothelia and smooth muscle cells. It is believed that suPAR mirrors the inflammatory response in patients. Previous studies have shown a strong association with mortality and severity of disease in a broad variety of conditions (infection, hepatic-, renal-, cardiac- and lung disease) as well as a possible marker of disease development in the general population. These abilities indicate that suPAR although unspecific would be ideal to identify patients at high- and at low-risk. The aim is to target interventions and limited clinical focus where it is most beneficial. In unselected patients suPAR is one of the strongest prognostic biomarker available to date.
It is not known whether information on prognosis in the Emergency department can be used to prevent death, serious complications or reduce admissions and readmissions.
The purpose of the current study is to examine if introduction of the biomarker suPAR and education of doctors in the meaning of suPAR levels and association to disease, can reduce mortality, admissions and readmission in patients referred to the emergency rooms.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Herlev, Denmark, 2730
- Herlev Hospital, Department of Cardiology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients presenting acutely to the Acute ward/Emergency department and have blood samples done which include both Hemoglobin, C reactive protein and Creatinine within 6 hours of registration within the study period. The study is carried out in 2 Hospitals in the Capital of Denmark.
Exclusion Criteria:
- Patients presenting in Pediatric, Gynecological or Obstetric units. Patients not being examined with blood samples.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Conventional
no suPAR measurement.
Standard care.
|
|
Experimental: suPAR
suPAR measurement and education of doctors working in the Emergency department in the meaning of low or elevated levels of suPAR.
Since suPAR is measured on all patients regardless of disease the investigators cannot define a single intervention.
A possible intervention depends on the clinical situation.
|
The biomarker suPAR will be measured on all patients included in the study.
Before the study period the doctors will receive information on suPAR.
We want to study if the information provided by suPAR is useful in emergency medicine.
Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease.
Usually a elevated suPAR level could result in more investigation e.g.
diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Cause Mortality
Time Frame: 10 months after the inclusions period ends mortality data will be assessed
|
Time frame starts at the beginning of the index admission, defined as first admission in the study period.
Patients will be followed using central registers.
|
10 months after the inclusions period ends mortality data will be assessed
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Cause Mortality
Time Frame: 1 months after index admission mortality data will assessed
|
Mortality within 30 days
|
1 months after index admission mortality data will assessed
|
Number of Discharges From the Emergency Room Within 24 Hours
Time Frame: 24 hours
|
How many patients are discharged directly from the ED
|
24 hours
|
Number of Admissions to the Medical Ward
Time Frame: 30 days
|
Number of Participants with Admissions to the Medical War
|
30 days
|
Number of Patients With an Admission to the Intensive Care Unit
Time Frame: 30 days
|
Number of Participants with transfer to the ICU
|
30 days
|
Number of Patients With New Cancer Diagnosis in Control vs Intervention Groups
Time Frame: 10 months after inclusion period ends
|
10 months after inclusion period ends
|
|
Length of Stay During Admission.
Time Frame: 30 days
|
Length of stay in days during the admission
|
30 days
|
Number of Readmissions
Time Frame: 90 days
|
Patients will be followed using central registers.
All new admissions within 90 days of the same patient is defined as readmissions.
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Kasper K Iversen, MD, DMSci, Department of Cardiology, Herlev Hospital
Publications and helpful links
General Publications
- Schultz M, Rasmussen LJH, Hoi-Hansen T, Kjoller E, Jensen BN, Lind MN, Ravn L, Kallemose T, Lange T, Kober L, Rasmussen LS, Eugen-Olsen J, Iversen KK. Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy. Dis Markers. 2019 May 19;2019:3403549. doi: 10.1155/2019/3403549. eCollection 2019.
- Schultz M, Rasmussen LJH, Kallemose T, Kjoller E, Lind MN, Ravn L, Lange T, Kober L, Rasmussen LS, Eugen-Olsen J, Iversen K. Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial. Scand J Trauma Resusc Emerg Med. 2019 Apr 11;27(1):43. doi: 10.1186/s13049-019-0621-7.
- Schultz M, Rasmussen LJH, Andersen MH, Stefansson JS, Falkentoft AC, Alstrup M, Sando A, Holle SLK, Meyer J, Tornkvist PBS, Hoi-Hansen T, Kjoller E, Jensen BN, Lind M, Ravn L, Kallemose T, Lange T, Kober L, Rasmussen LS, Eugen-Olsen J, Iversen KK. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III). Scand J Trauma Resusc Emerg Med. 2018 Aug 28;26(1):69. doi: 10.1186/s13049-018-0539-5.
- Sando A, Schultz M, Eugen-Olsen J, Rasmussen LS, Kober L, Kjoller E, Jensen BN, Ravn L, Lange T, Iversen K. Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial. Scand J Trauma Resusc Emerg Med. 2016 Aug 5;24:100. doi: 10.1186/s13049-016-0290-8.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HerlevH01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Triage
-
Kepler University HospitalCompleted
-
Turku University HospitalUnknownArtificial Intelligence | Triage
-
Emergency Medical Services, Capital Region, DenmarkRigshospitalet, Denmark; University of Copenhagen; Copenhagen University Hospital... and other collaboratorsCompletedEfficacy, Self | Pediatrics | TriageDenmark
-
M.D. Anderson Cancer CenterCompleted
-
Andreas MeerCantonal Hospital of BadenCompleted
-
Sophiahemmet UniversityFalck Ambulance A/S; CrashCourse ABRecruitingTraining | Triage | Learning | Mass Casualty IncidentSweden
-
Chang Gung Memorial HospitalChanghua Christian Hospital; Taipei City HospitalUnknownFrail Elderly Syndrome | TriageTaiwan
-
Rawalpindi Medical CollegeCompleted
-
University Hospital, GenevaCompleted
Clinical Trials on suPAR measurement
-
University Hospital, Clermont-FerrandCompletedDisease | Emergencies | In-hospital ObservationFrance
-
Helsinki University Central HospitalUniversity of CopenhagenCompleted
-
First Affiliated Hospital of Zhejiang UniversityCompletedAcute-On-Chronic Liver Failure | Cirrhosis and Chronic Liver Disease
-
University of CologneCompleted
-
University of MessinaUniversity of CataniaCompleted
-
Ege UniversityCompletedSeptic Shock | Sepsis, SevereTurkey
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
University of Southern DenmarkCompletedPneumonia, BacterialDenmark
-
Wroclaw Medical UniversityCompletedRecurrence | Progression | Biomarkers | Bladder Cancer | Non-muscle Invasive Bladder Cancer | CystoscopyPoland
-
ASST Fatebenefratelli SaccoFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Careggi Hospital; University Hospital Tuebingen and other collaboratorsNot yet recruitingPericarditisGermany, Italy